# Gemcitabine

## Gemzar inj 200mg

| TAH Drug Code      | [**IGEM**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IGEM)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | 1-line treatment of metastatic breast cancer (in combination with paclitaxel) after failure of adjuvant chemotherapy which contained an anthracycline (unless contraindicated). 1-line treatment (in combination with cisplatin) of inoperable, locally advanced (stage IIIA or IIIB) or metastatic (stage IV) non-small cell lung cancer (NSCLC). Treatment of advanced ovarian cancer, pancreatic cancer (locally advanced or metastatic).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Dosing             | [Ovarian Cancer] 1000 mg/m2 as an intravenous infusion over 30 minutes on Days 1 and 8 of each 21-day cycle, in combination with carboplatin AUC 4 intravenously after Gemzar administration on Day 1 of each 21-day cycle. [Breast Cancer] 1250 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle that includes paclitaxel. Paclitaxel should be administered at 175 mg/m2 on Day 1 as a 3-hour intravenous infusion before Gemzar. [Non-Small Cell Lung Cancer] Every 4-week schedule: 1000 mg/m2 over 30 minutes on Days 1, 8, and 15 in combination with cisplatin 100 mg/m2 on Day 1 after Gemzar. Every 3-week schedule: 1250 mg/m2 over 30 minutes on Days 1 and 8 in combination with cisplatin 100 mg/m2 on Day 1 after Gemzar. [Pancreatic Cancer] 1000 mg/m2 over 30 minutes intravenously.The recommended treatment schedule:‧ Weeks 1-8: weekly dosing for the first 7 weeks followed by one week rest.‧ After Week 8: weekly dosing on Days 1, 8, and 15 of 28-day cycles. [Bladder cancer] 1000 mg/m2 over 30 minutes on days 1, 8, and 15 in combination with cisplatin 70 mg/m2 on day 1; repeat cycle every 28 days. [Biliary tract cancer] 1000 mg/m2 as a single agent over 30 minutes once weekly for 3 weeks followed by 1 week rest; repeat cycle every 28 days. 1000 mg/m2 over 30 minutes in combination with cisplatin 25 mg/m2 on Days 1 and 8; repeat cycle every 21 days.                                                                                                 |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Contraindications  | Patients with a known hypersensitivity to gemcitabine.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Adverse Effects    | Myelosuppression with anemia, leukopenia or thrombocytopenia; nausea & vomiting, diarrhea & stomatitis; transient elevations in serum transminases; mild proteinuria & hematuria, hemolytic uremic syndrome (discontinue); fever & flu-like symptoms; rash, pruritus; dyspnea, occasionally accompanied by bronchospasm, pulmonary toxicity (discontinue); edema; infections, sepsis (rare); alopecia; paresthesia; inj site reactions; allergic reactions; CV events (rare). Cardiovascular: Peripheral edema (20% ) Dermatologic: Alopecia (15% to 90% ), Rash (10% to 30% ) Endocrine metabolic: Hyperglycemia (30% ), Hypomagnesemia (30% ) Gastrointestinal: Constipation (10% to 42%), Diarrhea (14% to 25% ), Nausea and vomiting (64% to 96% ), Stomatitis Hematologic: Anemia, All grade (65% to 89% ), Leukopenia, All grade (21% to 86% ), Neutropenia, All grade (62% to 90% ), Thrombocytopenia, All grade (24% to 85% ) Hepatic: Alkaline phosphatase raised (16% to 71% ), ALT/SGPT level raised (6% to 72% ), AST/SGOT level raised (3% to 72% ) Immunologic: Infectious disease (8 to 28% ) Musculoskeletal: Arthralgia (24% ), Myalgia (33% ) Neurologic: Paresthesia (2% to 38% ), Peripheral motor neuropathy (15% to 35% ), Sensory neuropathy (23% to 64% ) Otic: Hearing disorder (25% ) Renal: Hematuria (13% to 35% ), Proteinuria (10% to 45% ), Serum creatinine raised (2% to 38% ) Respiratory: Dyspnea (1% to 23% ) Other: Fatigue (40% ), Fever (6% to 41% ), Pain (10% to 48% ) |
| Pregnancy          | Contraindicated – 1st Trimester                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

